[Frequency and type of gifts given by pharmaceutical industry to cardiology residents]

Ghassan Moubarak1, Raphaël Pedro Martins, Stéphane Zuily

  • 1Service de cardiologie, Hôpital Lariboisière, 75010 Paris, France. ghassan.moubarak@gmail.com

Presse Medicale (Paris, France : 1983)
|April 20, 2010
PubMed

Insights

Cardiology residents in France frequently engage with pharmaceutical companies, receiving gifts and support for medical education. Most residents view these interactions as appropriate, highlighting a need for ethics training on industry influence.

Area of Science:

  • Cardiology
  • Medical Education
  • Pharmaceutical Industry Interactions

Context:

  • Cardiovascular diseases are a leading global cause of mortality.
  • Cardiologists are a key demographic for pharmaceutical marketing.
  • Understanding resident exposure to industry is crucial for medical ethics.

Purpose:

  • To evaluate the extent of cardiology residents' exposure to pharmaceutical companies.
  • To assess residents' perceptions of the appropriateness of these interactions.
  • To determine the value of gifts and support provided by the industry.

Summary:

  • A survey of French cardiology residents revealed widespread interaction with pharmaceutical companies.
  • Most residents received promotional items and invitations to congresses, considering them ethically appropriate.
  • A significant portion of residents believed gifts valued up to 1000 euros or more could influence judgment.

Impact:

  • Findings suggest frequent and generally accepted pharmaceutical industry engagement among cardiology residents.
  • Highlights the need for formal training on the ethical implications of industry interactions and prescribing influence.
  • Informs strategies for maintaining physician independence and patient-centered care.
Abstract

Related Concept Videos

Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...